1.0
8 Feb 2020
Former employee, more than 10 years
Cambridge, MA
Recommend
CEO approval
Business outlook
Pros
Stock options, medical benefits and year end bonus.
Cons
This once great company has been decimated and the staff demoralized by the greedy senior management which has wasted tens of billions of dollars on share buybacks to appease Wall Street and large shareholders. This money would have been better spent on more astute funding of research and superior scientific leaders. The main reason for the share buybacks is to maintain their EPS even though their revenues have been declining for the past few years. In addition, the decimation of the Cambridge site(Neuroscience, HTS, PKDM, Chemistry, and Toxicology) is an abomination and a perfect example of the treachery/greed/shortsightedness of the corrupt bourgeoisie of Thousand Oaks, CA.